Needham & Company initiates coverage on ImmunoGen, Inc. (Nasdaq: IMGN) with an Underperform rating.

Needham analyst says, "We believe the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE